LIFE SCIENCES - The Food and Drug Administration has approved Sepracor's new drug application for a hydrofluoroalkane metered-dose inhaler version of Xopenex, a treatment for respiratory disorders including asthma and chronic obstructive pulmonary disease.
Year of publication:
2005
Published in:
Chemical marketing reporter. - New York, NY : Schnell, ISSN 0090-0907, ZDB-ID 1213490. - Vol. 267.2005, 12, p. 8